{"id":"hemay005","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5095240","moleculeType":"Small molecule","molecularWeight":"466.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details for Hemay005 are limited in public literature, it is being developed by Ganzhou Hemay Pharmaceutical as an oncology therapeutic in Phase 3 trials. The drug likely works by inhibiting intracellular signaling pathways critical to tumor growth, though the exact molecular target requires confirmation from clinical trial data.","oneSentence":"Hemay005 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:58.419Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer indication (specific type not publicly confirmed)"}]},"trialDetails":[{"nctId":"NCT07314242","phase":"PHASE2","title":"A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD","status":"NOT_YET_RECRUITING","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2026-01-01","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":120},{"nctId":"NCT06908642","phase":"PHASE1","title":"Evaluation the Safety of hemay005 Tablets","status":"COMPLETED","sponsor":"Anhui Hemay Pharmaceutical Co., Ltd","startDate":"2024-12-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":468},{"nctId":"NCT06376474","phase":"PHASE1","title":"To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage","status":"RECRUITING","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2024-04-28","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT06380153","phase":"PHASE1","title":"To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment","status":"COMPLETED","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2024-05-07","conditions":"Psoriasis","enrollment":26},{"nctId":"NCT06610890","phase":"PHASE1","title":"Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets","status":"COMPLETED","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2024-12-12","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT06145893","phase":"PHASE3","title":"A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease","status":"RECRUITING","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2023-11-13","conditions":"Behçet's Disease","enrollment":162},{"nctId":"NCT05486104","phase":"PHASE2","title":"Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2022-11-08","conditions":"Moderate to Severe Ulcerative Colitis","enrollment":92},{"nctId":"NCT06610903","phase":"PHASE1","title":"Bioequivalence Test of Hemay005 Tablets","status":"COMPLETED","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2024-09-15","conditions":"Psoriasis","enrollment":28},{"nctId":"NCT04837235","phase":"PHASE1","title":"Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects","status":"COMPLETED","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2021-04-29","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT05941247","phase":"PHASE1","title":"A Study to Evaluate the Effects of Single and Multiple Doses of Hemay005 Tablets in Health Caucasian Adult Volunteers","status":"COMPLETED","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2023-07-17","conditions":"Healthy","enrollment":12},{"nctId":"NCT05769946","phase":"PHASE2","title":"A Study of Hemay005 in Adult With Atopic Dermatitis","status":"COMPLETED","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2022-11-24","conditions":"Hemay005, Atopic Dermatitis","enrollment":79},{"nctId":"NCT05468645","phase":"PHASE1","title":"In Vivo Mass Balance Study of [14C]Hemay005","status":"COMPLETED","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","startDate":"2022-07-25","conditions":"Health Volunteer","enrollment":6},{"nctId":"NCT04839328","phase":"PHASE3","title":"A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2022-01-20","conditions":"Psoriasis","enrollment":306},{"nctId":"NCT05407246","phase":"PHASE2","title":"Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2022-08-05","conditions":"Active Ankylosing Spondylitis","enrollment":90},{"nctId":"NCT04609397","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease","status":"TERMINATED","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2020-11-30","conditions":"Behçet Disease","enrollment":89},{"nctId":"NCT04102241","phase":"PHASE2","title":"Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2019-05-30","conditions":"Psoriasis","enrollment":216},{"nctId":"NCT03570346","phase":"PHASE1","title":"Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects","status":"UNKNOWN","sponsor":"Tianjin Hemay Bio-Tech Co., Ltd","startDate":"2018-07-10","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT03577626","phase":"PHASE1","title":"A Food Effect Study to Assess Pharmacokinetics of Hemay005 in Healthy Volunteers","status":"UNKNOWN","sponsor":"Tianjin Hemay Bio-Tech Co., Ltd","startDate":"2018-10-10","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT03007810","phase":"PHASE1","title":"Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects","status":"COMPLETED","sponsor":"Tianjin Hemay Bio-Tech Co., Ltd","startDate":"2016-12","conditions":"Psoriasis","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hemay005 tablet","placebo","Phosphodiesterase 4 (PDE4) inhibitors","Mufemilast"],"phase":"phase_3","status":"active","brandName":"Hemay005","genericName":"Hemay005","companyName":"Ganzhou Hemay Pharmaceutical Co., Ltd","companyId":"ganzhou-hemay-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hemay005 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival. Used for Cancer indication (specific type not publicly confirmed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}